Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc (CRVS)
NASDAQ:CRVS
Top Page
Corvus Pharmaceuticals
(NASDAQ:CRVS)
Rating:41Neutral
Price Target:―
Positive Factors
Clinical Progress
Corvus Pharmaceuticals is advancing its atopic dermatitis clinical program and is ready to move soquelitinib into a Phase 2 study following strong results.
Regulatory Approvals
The company's partner in China, Angel Pharmaceuticals, has received regulatory clearance to initiate a Phase 1/2 study in China, expanding the geographical scope of clinical testing.
Negative Factors
Financial Performance
For the quarter, the company reported no revenues and a net loss of $0.13 per diluted share, compared to consensus estimated net loss of $0.12 per share.
Market Reaction
The significant drop in CRVS shares is seen as an overreaction, potentially due to market disappointment with soquel's efficacy compared to Dupixent.
Corvus Pharmaceuticals (CRVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$412.81M
Dividend YieldN/A
Average Volume (3M)479.21K
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue GrowthN/A
EPS Growth-50.83%
CountryUS
Employees31
SectorHealthcare
Sector Strength47
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding74,514,040
10 Day Avg. Volume538,194
30 Day Avg. Volume479,211
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue2.70K
Enterprise Value/Gross Profit-8.81K
Enterprise Value/Ebitda-6.70
Forecast
1Y Price Target
$12.33Price Target Upside127.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Corvus Pharmaceuticals Business Overview & Revenue Model
Company DescriptionCorvus Pharmaceuticals (CRVS) is a biotechnology company focused on the development and commercialization of innovative immuno-oncology therapies. The company is engaged in the research and development of novel drugs designed to harness the immune system to treat cancer. Corvus Pharmaceuticals' core product pipeline includes small molecule and antibody therapies targeting various immune checkpoints and pathways crucial for cancer treatment.
How the Company Makes MoneyCorvus Pharmaceuticals generates revenue primarily through the development and potential commercialization of its immuno-oncology drug candidates. The company typically seeks to advance its drug candidates through clinical trials and may enter into licensing agreements or partnerships with larger pharmaceutical companies to co-develop or market these treatments. Additionally, Corvus may receive milestone payments and royalties from its partners based on the success and sales of the developed drugs. Grants and research funding from governmental or non-profit organizations can also contribute to its revenue streams.
Corvus Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 07, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant clinical progress, particularly with soquelitinib, and a strong cash position, offset by increased net loss and R&D expenses. The positive clinical data and financial stability indicate a promising outlook despite financial challenges.Q2-2025 Updates
Positive Updates
Increased Cash Position
Corvus Pharmaceuticals increased its cash, cash equivalents, and marketable securities to $74.4 million as of June 30, 2025, compared to $52 million at December 31, 2024, partly due to common stock warrants exercise resulting in $35.7 million cash proceeds.
Encouraging Clinical Trial Results for Soquelitinib
The Phase I trial for soquelitinib in atopic dermatitis showed promising results, with Cohort 3 demonstrating a mean percent reduction of EASI score of 64.8% compared to 54.6% for previous cohorts and 34.4% for placebo. 50% of patients in Cohort 3 achieved EASI-75.
Advancement of Soquelitinib Clinical Trials
Corvus Pharmaceuticals is advancing soquelitinib with a planned Phase II trial for atopic dermatitis and an extension Cohort 4, continuing to demonstrate favorable safety and efficacy profiles.
Successful Completion of Stock Warrant Exercise
All remaining common stock warrants were exercised during the quarter, providing additional capital and demonstrating investor confidence.
Negative Updates
Increased Net Loss
Corvus reported a net loss of $8 million for Q2 2025, a significant increase from the $4.3 million net loss in the same period in 2024, driven by higher R&D expenses and personnel-related costs.
Higher Research and Development Expenses
R&D expenses increased to $7.9 million in Q2 2025 from $4.1 million in Q2 2024, attributed to higher clinical trial and manufacturing costs and increased personnel expenses.
Company Guidance
During the Corvus Pharmaceuticals second-quarter 2025 business update and financial results conference call, significant guidance was provided on various metrics concerning the company's financial and clinical progress. Research and development expenses increased to $7.9 million in Q2 2025 from $4.1 million in the same period in 2024, primarily due to soquelitinib development costs. The net loss for the quarter was $8 million, including a $400,000 noncash loss related to Angel Pharmaceuticals, with a noncash gain of $2 million from changes in Corvus' warrant liability. Stock compensation expense rose to $1.3 million from $800,000 a year earlier. Corvus reported cash, cash equivalents, and marketable securities totaling $74.4 million as of June 30, 2025. Key clinical updates included promising Phase I trial data for soquelitinib in atopic dermatitis, with a mean percent reduction in EASI score of 64.8% in Cohort 3. The company plans a Phase II trial with approximately 200 patients to assess different dosing regimens. Additionally, Corvus is advancing trials for soquelitinib in T-cell lymphoma and autoimmune lymphoproliferative syndrome, with ongoing efforts to explore next-generation ITK inhibitors.Corvus Pharmaceuticals Financial Statement Overview
Summary
Corvus Pharmaceuticals is facing significant financial challenges with no revenue and ongoing losses. The balance sheet is stable with low leverage, but declining equity poses risks. Cash flow issues persist, driven by negative operational results and reliance on financing activities for liquidity.Income Statement
Corvus Pharmaceuticals has consistently reported zero revenue over the years, indicating a lack of commercial success or product launches. The company also reports significant net losses, with no visible improvement in net profit margin. The EBIT and EBITDA margins are non-existent due to the absence of revenue, highlighting ongoing operational challenges.20
Very Negative
Balance Sheet
The balance sheet shows a relatively low debt-to-equity ratio, suggesting limited leverage with a Total Debt of $1.12 million against a Stockholders' Equity of $32.57 million. Despite this, the equity ratio has declined, pointing to potential risks as liabilities increase. The company has a declining stockholders' equity over the years, indicating potential financial vulnerability.40
Negative
Cash Flow
The cash flow statement reveals negative operating and free cash flows, demonstrating cash burn with no revenue inflows. Despite a recent increase in financing cash flow, the reliance on external financing is a concern. Free cash flow remains negative, reflecting continuous operational cash challenges.30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 88.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.00K | -85.00K | -151.00K | -367.00K | -460.00K | -632.00K |
| EBITDA | -35.48M | -27.55M | -26.88M | -40.94M | -42.78M | -5.36M |
| Net Income | -45.13M | -62.29M | -27.03M | -41.31M | -43.24M | -6.00M |
Balance Sheet | ||||||
| Total Assets | 89.46M | 68.91M | 45.55M | 68.24M | 109.45M | 85.53M |
| Cash, Cash Equivalents and Short-Term Investments | 74.41M | 51.96M | 27.15M | 42.30M | 69.45M | 44.26M |
| Total Debt | 1.08M | 1.12M | 1.37M | 2.60M | 3.65M | 2.31M |
| Total Liabilities | 9.23M | 36.34M | 6.87M | 12.13M | 12.29M | 13.38M |
| Stockholders Equity | 80.23M | 32.57M | 38.68M | 56.12M | 97.16M | 72.15M |
Cash Flow | ||||||
| Free Cash Flow | -28.98M | -25.42M | -23.97M | -27.29M | -36.72M | -34.85M |
| Operating Cash Flow | -28.83M | -25.42M | -23.93M | -27.02M | -36.72M | -34.78M |
| Investing Cash Flow | -26.03M | -27.48M | 15.54M | -23.28M | 21.56M | 44.77M |
| Financing Cash Flow | 54.71M | 49.03M | 7.86M | 0.00 | 62.16M | 1.31M |
Corvus Pharmaceuticals Technical Analysis
Positive
5.41
Price Trends
4.48
Positive
4.05
Positive
4.86
Positive
Market Momentum
0.32
Negative
63.57
Neutral
63.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVS, the sentiment is Positive. The current price of 5.41 is above the 20-day moving average (MA) of 4.90, above the 50-day MA of 4.48, and above the 200-day MA of 4.86, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 63.57 is Neutral, neither overbought nor oversold. The STOCH value of 63.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRVS.
Corvus Pharmaceuticals Risk Analysis
Corvus Pharmaceuticals disclosed 73 risk factors in its most recent earnings report. Corvus Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Corvus Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $746.55M | 7.34 | 376.09% | ― | 105.62% | ― | |
51 Neutral | $7.81B | -0.22 | -40.01% | 2.29% | 21.48% | -2.11% | |
51 Neutral | $303.60M | ― | -55.91% | ― | -95.11% | 27.25% | |
44 Neutral | $376.42M | ― | -38.49% | ― | ― | 11.81% | |
41 Neutral | $412.81M | ― | -68.67% | ― | ― | -50.83% | |
40 Underperform | $365.79M | ― | -69.65% | ― | ― | 10.36% | |
34 Underperform | $285.72M | ― | -39.41% | ― | -100.00% | -24.84% |
* Healthcare Sector Average
Performance Comparison
CRVS
Corvus Pharmaceuticals
5.41
1.27
30.68%
ALT
Altimmune
3.71
-2.90
-43.87%
RIGL
Rigel
39.31
25.76
190.11%
NGNE
Neurogene
18.84
-17.56
-48.24%
RCKT
Rocket Pharmaceuticals
3.35
-15.43
-82.16%
ATXS
Astria Therapeutics
6.53
-5.49
-45.67%
Corvus Pharmaceuticals Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Corvus Pharmaceuticals Appoints New Director to Board
Positive
Apr 9, 2025
On April 8, 2025, Corvus Pharmaceuticals appointed Richard van den Broek as a Class II director, with his term expiring at the 2027 annual meeting. He was also appointed to the Audit and Nominating Committees. This strategic appointment is expected to strengthen the company’s governance and oversight, potentially impacting its operational effectiveness and stakeholder confidence.
Spark’s Take on CRVS Stock
According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.
Corvus Pharmaceuticals faces significant financial challenges, with no revenue and increasing losses. Technical indicators show a bearish trend, and valuation metrics are weak. However, the earnings call highlighted clinical advancements, which provide some optimism. Overall, the stock is rated at the lower end of the scale due to its financial difficulties and negative technical trends, with some potential upside from clinical developments.
To see Spark’s full report on CRVS stock, click here.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.